IndraLab

Statements

AAV-NaVbeta1 activates SCN1A. 7 / 7
| 7
reach
"Male Scn1a +/- mice treated with AAV-NaVbeta1 showed reduced spontaneous seizures and normalization of motor activity and performance on the elevated plus maze test."
31830809
reach
"Survival of Scn1a +/- mice treated with AAV-NaVbeta1."
31830809
reach
"In contrast, WT and Scn1a +/- treated with AAV-NaVbeta1 did not differ in the time spent in the open arms, indicating correction of this endophenotype after treatment with AAV-NaVbeta1 (XREF_FIG; treatment main effect, F 1,62 = 3.66, p < 0.01; genotype main effect, F 1,62 = 8.08, p < 0.01)."
31830809
reach
"In contrast, there was no statistical difference in the frequency of tonic seizures in the female Scn1a +/- mice treated with AAV-NaVbeta1 compared with female Scn1a +/- mice with AAV-EV (XREF_FIG; t = 0.75, p> 0.05)."
31830809
reach
"However, in the AAV-NaVbeta1 treatment groups, Scn1a +/- mice treated with AAV-NaVbeta1 traveled farther than WT mice treated with either AAV-EV or AAV-NaVbeta1 (XREF_FIG; genotype main effect, F 1,62 = 9.32, p < 0.01)."
31830809
reach
"24 In the passive avoidance test, female Scn1a +/- mice treated with AAV-EV or with AAV-NaVbeta1 both displayed reduced latency to crossover compared with WT mice injected with AAV-EV (XREF_FIG; treatment main effect, F 1,46 = 1.90, p < 0.01)."
31830809
reach
"Using the anti-NaVbeta1 antibody, the level of total NaVbeta1 protein in Scn1a +/- mice treated with AAV-NaVbeta1 was 8.3 times higher compared with WT mice treated with AAV-EV (XREF_FIG), whereas using an anti-c-myc antibody to assess transgene generated NaVbeta1 revealed similar levels in WT and Scn1a +/- mice treated with AAV-NaVbeta1 (XREF_FIG)."
31830809